Secretory Phospholipase A2 Tipe Ii (Spla Ii) pada Penyakit Kardiovaskuler

  • Djanggan Sargowo Fakultas Kedokteran Universitas Brawijaya, dan Rumah Sakit Saiful Anwar Malang.
Keywords: phospholipase, iskemia, infeksi/inflamasi, atherosclerosis

Abstract

Reaksi inflamasi berperan dalam beberapa pathogenesis kondisi kardiovaskuler seperti atherosklerosis dan kerusakan iskemikpada infark miokard akut (IMA). Di antara mediator-mediator yang terlibat dalam inflamasi tersebut adalah enzim secretoryphospholipase A2 tipe II (sPLA2-II). Meskipun beberapa sel memang memproduksi sPLA2-II, namun sintesis oleh sel-sel tertentuseperti hepatosit, adalah khas sebagai reaktan fase akut. Literatur terbaru menyatakan banyaknya peran dari sPLA2-II dalampenyakit kardiovaskuler. Dalam tulisan berikut, akan mendiskusikan peran sPLA2-II dalam berbagai model atherosklerosisatau IMA, baik in vitro maupun in vivo, termasuk perspektif terapeutik dari sPLA2-II inhibitor. Disimpulkan bahwa sPLA2-IImerupakan mediator inflamasi yang penting dalam penyakit kardiovaskuler.

Downloads

Download data is not yet available.

Author Biography

Djanggan Sargowo, Fakultas Kedokteran Universitas Brawijaya, dan Rumah Sakit Saiful Anwar Malang.
Departemen Kardiologidan Kedokteran Vaskular

References

Lagrand WK, Visser CA, Hermens WT et al. C-reactive protein

as a cardiovascular risk factor? Circulation 1999;100;96-102

Wiklund O, Mattsson-Hulten L, Hurt-Camejo E et al. Effects

Gambar 2. Overview peran sPLA2-II pada atherosclerosis

dan kerusakan cardiomyocyte post IMA. Pada pembuluh

darah, sPLA2-II menginduksi atherosclerosis. sPLA2-II

ditemukan pada plak atherosclerotic di mana sPLA2-II

menginduksi peningkatan (small dense) LDL, penurunan

HDL, dan memicu makrofag untuk mengekspresikan

enzim tertentu dan membentuk foam cell. Atherosclerosis

dapat memicu IMA. sPLA2-II menginduksi kerusakan

cardiomyocyte selama reaksi inflamasi akibat iskemia

miokard. sPLA2-II dapat berikatan dengan membran

flip flop [PE dan PS] sehingga menyebabkan kematian

sel melalui aktivasi caspase 3, yang menyebabkan nekrosis

sekunder. sPLA2-II juga menginduksi ikatan CRP yang akan

menginduksi aktivasi komplemen sehingga menimbulkan

nekrosis sekunder. (Niessen. HWM. Caerdiovascular R.

Sargowo D: Spla Ii pada Penyakit Kardiovaskular

Jurnal Kardiologi Indonesia • Vol. 34, No. 4 • Oktober - Desember 2013 279

of simvastatin and atorvastatin on inflammation markers in

plasma. J Intern Med 2002; 251;338-347.

Ross R. Atherosclerosis: An inflamatory disease. N Engl J Med

; 340; 115 – 126

Morre SA, Stooker W, Lagrand WK et al. Microorganisms in the

aetiology of atherosclerosis, J Clin Pathol 2000;53:647-654

Libby P, Maroko PR, Bloor CM et al. Reduction of experimental

myocardial infarct size by corticosteroid administration. J Clin

invest 1973;52;599-607.

Maroko PR, Carpenter CB, Chiarillo M et al. Reduction by

cobra venom factor of myocardial necrosis after coronary artery

occlusion. J Clin Invest 1978;61:661-670.

De Zwaan C, Kleine AH, Diris JH et al. Continuous 48-h Cl

inhibitor treatment, following reperfusion theraphy, in patients

with accute myocardial infarction. Eur Heart J 2002;23:1670-

Snitko Y, Yoon ET, Cho . High specificity of human secretory

class II phospholipase A2 for phosphatidic acid. Biochem J

;321:737-754

Baker SF, Othman R, Wilton DE, Tryptophan-caontaining

mutant of human (group Iia) secreted phospholipase A2 has a

dramatically increased ability to hydrolize phosphatidilcholine

vesicle and cell membranes. Biochemistry 1998;161:5008-

Hernandez M, Burillo SL, Crespo SL, Crespo MS et al. Secretory

phospholipase A2 activates the cascade of mitogen-activated

protein kinase and cytosolic phospolipase A2 in the human astrocytoma

cell line 1321N1. J Biol Chem 1998;273:606-612.

Kutawa H, Yamamoto S, Miyazaki Y et al. Studies on a

mechanism by which cytosolic phohpolipase A2. J Immunol

;165:4024-4031.

Marshall J, Krump E, Lindsay T et al. Involvement of cytosolic

phospholipase A2 and secretory phospholipase A2 in

arachidomic acid release from human neutrophils. J Immunol

;164:2084-2091.

Thommesen L, Sjursen W. Gasvik K et al. Selective inhibitors

of cytosolic or secretory phospholipase A2 block TNF-induced

activeation of transcription factor kappa-B and expression of

ICAM-1. J Immunol 1998;161:3421-3430.

Milella M, Gismondi A, Roncaioli P et al. CD 16 cross-linking

induces both secretory and extracelullar signal-regulated kinase

(ERK)-dependent cytosolic phospholipase A2 (PLA2) acrivity

in human natural killer cells: involvement of ERK, but

not PLA2, in CD16-triggered granule exocytosis. J Immunol

;158:3148-3154.

Eckey R, Menschikowsaki M, Yamamoto S et al, Minimal

oxidation and storage of low density lipoproteins result in an

increased susceptibility to phospolipase A2. Atherosclerosis

;19:165-176.

Kugiyama K, Ota Y, Sugiyama S et al. Prognosis value of plasma

levels of secretory type II phospholipase A2 in patients with

unstable angina pectoris. Am J Cardiol 2000;86:718-722

Menschikowski M, Kasper M, Lattke P et al. Analysis of secretory

group II phospholipase A2 in human aortic plaques.

Atherosclerosis 1995;118:173-181.

Schiering A, Menschikowski M, Mueller E et al. Analysis of

secretory group II phospholipase A2 in human aortic tissue is

dependence on the degree of etherosclerosis. Atherosclerosis

;144:73-78.

Elinder LS, Demitrescu A. Larsson P et al, Expression of phoepholipase

A2 isoform in human normal and arterosclerosis arterial

wall. Arterioscler Throm Vasc Biol 1997;17: 2257-2263.

Published
2015-04-01

Abstract viewed :
58 times
PDF downloaded : 94 times

How to Cite
Sargowo, D. (2015). Secretory Phospholipase A2 Tipe Ii (Spla Ii) pada Penyakit Kardiovaskuler. Indonesian Journal of Cardiology, 34(4), 271-9. https://doi.org/10.30701/ijc.v34i4.386
Section
Review Article